Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CICLOPIROX vs AMBISOME
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ciclopirox is a hydroxypyridone antifungal agent that chelates polyvalent metal cations (e.g., Fe3+, Al3+) inhibiting metal-dependent enzymes, thereby disrupting fungal cellular metabolic processes, including mitochondrial electron transport and energy production.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and fungal cell death.
Topical treatment of tinea pedis, tinea cruris, tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis,Treatment of seborrheic dermatitis of the scalp,Treatment of cutaneous candidiasis (moniliasis) due to Candida albicans,Treatment of onychomycosis of fingernails and toenails due to Trichophyton rubrum,Off-label: Treatment of tinea versicolor, vaginal candidiasis, and superficial dermatophyte infections
Empirical therapy for presumed fungal infection in febrile neutropenic patients,Treatment of cryptococcal meningitis in HIV-infected patients,Treatment of visceral leishmaniasis,Treatment of invasive aspergillosis (alternate therapy),Treatment of candidiasis (invasive and mucosal),Treatment of histoplasmosis (severe disseminated),Treatment of blastomycosis (severe),Treatment of coccidioidomycosis (severe),Treatment of mucormycosis,Treatment of fusariosis,Treatment of talaromycosis (penicilliosis)
Ciclopirox 8% nail lacquer: Apply to affected nails once daily for up to 48 weeks. Ciclopirox 1% cream or lotion: Apply to affected skin twice daily for 2-4 weeks. Ciclopirox 1% shampoo: Apply to wet hair, lather, leave for 3 minutes, rinse; use twice weekly for 4 weeks (for seborrheic dermatitis).
3-5 mg/kg/day intravenously for systemic fungal infections; for visceral leishmaniasis: 3 mg/kg/day IV on days 1-5, 14, and 21.
Terminal elimination half-life: 1.7-3.0 hours in healthy individuals; prolonged in hepatic impairment
Terminal elimination half-life: approximately 7–10 hours (initial phase), with a prolonged terminal half-life of 100–153 hours due to slow redistribution from tissues; clinically, this supports once-daily dosing after initial accumulation.
Minimal systemic absorption following topical application. The small absorbed fraction is primarily metabolized via glucuronidation and oxidation. Unchanged drug and metabolites are excreted renally and fecally. Specific hepatic enzymes involved are not well characterized.
Amphotericin B is predominantly cleared via the reticuloendothelial system and is excreted slowly in urine and feces. Metabolism is not well characterized, but it is not extensively metabolized by liver enzymes.
Renal: approximately 70-80% of the absorbed dose as unchanged drug and glucuronide conjugates; biliary/fecal: ~20-30%
Renal: negligible (<1% unchanged); Biliary/fecal: primary route, approximately 90% of dose recovered in feces as parent drug and metabolites; Urinary: minimal (less than 1% as unchanged drug).
94-98% bound to plasma proteins, primarily albumin
Highly bound (>90%), primarily to albumin and alpha-1-acid glycoprotein.
1.2-2.0 L/kg, indicating extensive tissue distribution
Vd: 0.4–0.6 L/kg; reflects extensive tissue distribution, particularly into organs of the reticuloendothelial system (liver, spleen).
Topical: minimal systemic absorption (<1-5% of applied dose); oral: not formulated for systemic use
Intravenous: 100% (only route of administration).
No specific dose adjustments are recommended; systemic absorption is minimal (<1.3%) with topical application. For oral use (not available in the US), no data for renal impairment.
No dose adjustment required for renal impairment; use caution in patients with pre-existing renal disease and monitor renal function.
No dose adjustments needed for topical use due to negligible systemic absorption. No data for oral formulations.
No specific dose adjustment for Child-Pugh class A or B; for Child-Pugh class C, consider dose reduction or increased monitoring due to potential hepatotoxicity.
Ciclopirox 1% cream: Approved for children ≥10 years with tinea pedis or tinea corporis; apply twice daily for 2 weeks. Ciclopirox 8% nail lacquer: Not recommended in children <12 years. Ciclopirox 1% shampoo: Not established in children <16 years.
For systemic fungal infections: 3-5 mg/kg/day IV; for visceral leishmaniasis: 3 mg/kg/day IV on days 1-5, 14, and 21; weight-based dosing with no maximum daily dose specified.
No specific dose adjustments; topical use has minimal systemic absorption. Consider skin thinning and increased risk of irritation in elderly; use caution with prolonged application.
No specific dose adjustment; monitor renal function closely due to age-related decreased GFR and potential nephrotoxicity.
None currently listed in FDA labeling.
Amphotericin B products should be used primarily for treatment of severe fungal infections in immunocompromised patients where significant toxicity is justified. Amphotericin B is associated with severe nephrotoxicity, especially when used at higher doses or with other nephrotoxic agents. Infusion-related reactions (fever, chills, rigors, hypotension) are common and may be severe.
For external use only; avoid contact with eyes and mucous membranes,If irritation or sensitivity develops, discontinue treatment,Not for intravaginal or ophthalmic use,Use in diabetic patients may require additional monitoring for nail infections,Keep away from heat and open flame (ciclopirox solution contains alcohol)
Nephrotoxicity: Monitor renal function closely; avoid concomitant nephrotoxic drugs when possible.,Infusion reactions: Premedication (e.g., acetaminophen, antihistamines, corticosteroids) may reduce severity.,Electrolyte disturbances: Hypokalemia, hypomagnesemia may occur; monitor and replace as needed.,Hepatotoxicity: Monitor liver function tests.,Cardiotoxicity: Rarely associated with arrhythmias; caution in patients with cardiac disease.,Pancreatitis: Has been reported; consider in patients with abdominal pain.
Hypersensitivity to ciclopirox or any component of the formulation
Hypersensitivity to amphotericin B or any component of the formulation (unless the condition is life-threatening and amenable only to amphotericin B therapy)
No significant food interactions have been reported with topical ciclopirox. For oral ciclopirox (not available in the US), food may affect absorption; consult prescribing information.
No known significant food interactions. Grapefruit juice does not affect liposomal amphotericin B metabolism.
Topical ciclopirox has minimal systemic absorption ( < 1.5%) and is generally considered low risk. Animal studies with high doses have shown fetal toxicity, but no teratogenicity in rats or rabbits. For topical use, there is no evidence of teratogenicity in humans. However, sufficient data are lacking for first trimester risk. The drug should be used during pregnancy only if clearly needed, with caution primarily in first trimester.
Pregnancy Category A. No evidence of teratogenicity in animal studies; no adequate human studies in first trimester. In second and third trimesters, use only if clearly needed; no known fetal risks.
It is unknown if ciclopirox is excreted in human milk. Due to low systemic absorption after topical application, the amount ingested by a nursing infant is likely negligible. Use with caution on small areas and avoid application to breast. M/P ratio not established.
Excretion in human milk unknown; caution advised. M/P ratio not available.
No pharmacokinetic changes requiring dose adjustment have been reported for topical ciclopirox. Systemic absorption is minimal and pregnancy-induced changes in skin permeability or clearance are not expected to alter systemic exposure significantly. Standard topical dosing (apply twice daily to affected areas) is appropriate.
No dose adjustment required for systemic exposure in pregnancy; pharmacokinetic changes not significant.
Apply topical ciclopirox once or twice daily, covering the lesion and a 1 cm margin of normal skin. For nail infections, file away loose nail material before applying lacquer. Avoid occlusive dressings unless directed. Treatment duration for tinea pedis is 2 weeks; for tinea corporis/cruris, 2-4 weeks. For onychomycosis, treatment may require 48 weeks or until nail replacement.
Am Bisome (liposomal amphotericin B) is preferred over conventional amphotericin B due to reduced nephrotoxicity and infusion-related reactions. Dose adjustment not required in renal impairment, but monitor renal function closely. Premedication with acetaminophen, diphenhydramine, and hydrocortisone may reduce infusion reactions. For cryptococcal meningitis in HIV, combination with flucytosine is recommended. Not interchangeable with other amphotericin B formulations; verify dose and product before administration.
Wash hands before and after applying the medication.,Apply a thin layer to the affected area and rub in gently.,Do not use on open wounds, or in eyes, mouth, or vagina.,For nail lacquer, apply daily over the entire nail plate and to the underside of the nail tip.,Avoid nail polish or artificial nails during treatment.,Complete the full course even if symptoms improve.,Notify your doctor if irritation or allergic reaction occurs.
Take exactly as prescribed; do not skip doses or stop early.,Infusion reactions (fever, chills, nausea) may occur; report these to your healthcare provider.,Drink plenty of fluids unless advised otherwise by your doctor.,Contact your doctor immediately if you experience signs of allergic reaction (rash, itching, swelling, severe dizziness, trouble breathing).,Tell your doctor about all medications you are taking, including over-the-counter drugs and herbal supplements.,This medication can cause kidney problems; you will need regular blood tests.
"Combining ciclopirox, an antifungal agent, with benidipine, a calcium channel blocker, may result in increased toxicity or reduced therapeutic efficacy. Benidipine is metabolized via CYP3A4; ciclopirox can inhibit CYP3A4, potentially raising benidipine plasma concentrations and causing hypotension, dizziness, or peripheral edema. Additionally, ciclopirox may have additive cardiodepressant effects, leading to bradycardia or worsening heart failure in susceptible patients."
"Co-administration of Ciclopirox and Eperisone may lead to additive antagonism of normal muscle tone and coordination due to concurrent central nervous system depression. Ciclopirox, primarily used for dermatological conditions, has noted sedative effects from systemic absorption, while Eperisone centrally acts as a muscle relaxant with sedative properties. The combined use can potentiate drowsiness, dizziness, and impaired psychomotor function, increasing the risk of falls and accidents."
"Losartan, an angiotensin II receptor blocker, and ciclopirox, a topical antifungal, are not expected to have a clinically significant pharmacokinetic interaction. Ciclopirox is minimally absorbed through the skin (<0.01% of applied dose) and undergoes hepatic glucuronidation and renal excretion. Losartan is metabolized primarily by CYP2C9 and CYP3A4 to its active metabolite. The baseline statement suggests a theoretical inhibition of ciclopirox metabolism by losartan, but given ciclopirox's negligible systemic exposure after topical use and different metabolic pathways, this interaction is unlikely to produce adverse clinical outcomes."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CICLOPIROX vs AMBISOME, answered by our medical review team.
CICLOPIROX is a Antifungal that works by Ciclopirox is a hydroxypyridone antifungal agent that chelates polyvalent metal cations (e.g., Fe3+, Al3+) inhibiting metal-dependent enzymes, thereby disrupting fungal cellular metabolic processes, including mitochondrial electron transport and energy production.. AMBISOME is a Antifungal that works by Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and fungal cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CICLOPIROX and AMBISOME depend on the specific clinical indication. These are both Antifungal agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CICLOPIROX is: Ciclopirox 8% nail lacquer: Apply to affected nails once daily for up to 48 weeks. Ciclopirox 1% cream or lotion: Apply to affected skin twice daily for 2-4 weeks. Ciclopirox 1% shampoo: Apply to wet hair, lather, leave for 3 minutes, rinse; use twice weekly for 4 weeks (for seborrheic dermatitis).. The standard adult dose of AMBISOME is: 3-5 mg/kg/day intravenously for systemic fungal infections; for visceral leishmaniasis: 3 mg/kg/day IV on days 1-5, 14, and 21.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CICLOPIROX and AMBISOME in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CICLOPIROX is classified as Category A/B. Topical ciclopirox has minimal systemic absorption ( < 1.5%) and is generally considered low risk. Animal studies with high doses have shown fetal toxicity, but no teratogenicity i. AMBISOME is classified as Category C. Pregnancy Category A. No evidence of teratogenicity in animal studies; no adequate human studies in first trimester. In second and third trimesters, use only if clearly needed; no . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.